PHARMACYTE BIOTECH, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for the quarter ending 2026-04-30 was $0.00, a 100.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for the quarter ending 2026-01-31 was $401.63K, a 78.48% increase year-over-year.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for the quarter ending 2025-10-31 was $0.00, a 100.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for the quarter ending 2025-07-31 was $0.00, a 100.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for fiscal 2026 was $401.63K, a 84.20% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for fiscal 2025 was $2.54M, a 90.98% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for fiscal 2024 was $28.20M, a 107.94% increase from fiscal 2023.
- PHARMACYTE BIOTECH, INC. payments for repurchase of common stock for fiscal 2023 was $13.56M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $401.63K 10-K · filed 2026-07-29 |
| 2026-01-31 | $401.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $573.17K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | $396.57K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-07-31 | $0.00 10-Q · filed 2025-09-15 | $1.80M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-04-30 | $171.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $2.54M 10-K · filed 2026-07-29 |
| 2025-01-31 | $225.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $3.55M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | $3.73M derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | $742.18K 10-Q · filed 2025-09-15 | $2.49M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $28.20M 10-K · filed 2025-08-11 |
| 2024-01-31 | $404.72K 10-Q · filed 2024-03-18 | $31.33M derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-10-31 | $164.95K 10-Q · filed 2023-12-15 | $34.71M derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-07-31 | $26.46M 10-Q · filed 2024-09-17 | $37.93M derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-04-30 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | $13.56M 10-K · filed 2024-08-13 |
| 2023-01-31 | $3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-18 | $9.25M derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | $5.48M derived: sum of 4 quarters · filed 2023-12-15 |
| 2022-07-31 | $2.09M 10-Q · filed 2023-09-18 | $2.09M derived: sum of 4 quarters · filed 2023-09-18 |
| 2022-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-31 | $0.00 10-K · filed 2023-07-31 |
| 2022-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16 | |
| 2021-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-14 | |
| 2021-07-31 | $0.00 10-Q · filed 2022-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |